A phase 1/2 trial found that adding vilamakitug, an anti-IL-1α antibody, to standard chemotherapy met its 12-month survival threshold in refractory metastatic colorectal cancer. The benefit was especially striking in patients with right-sided tumors, where the drug cut the risk of death by 62%. Results point toward a biomarker-driven path for future development.
The TASKIN trial has delivered encouraging news for patients with refractory metastatic colorectal cancer (mCRC). Adding vilamakitug — a monoclonal antibody targeting interleukin-1α (IL-1α) — to standard-of-care trifluridine/tipiracil (with or without bevacizumab) met its prespecified 12-month overall survival (OS) threshold, with 61.3% of patients in the vilamakitug arm alive at 12 months vs. 55.7% in the placebo arm.
The most compelling signal came from a prospective exploratory analysis of patients with right-sided (proximal) primary tumors, where vilamakitug-based therapy slashed the risk of death by 62% compared to control — a finding that could shape how the drug is developed going forward.
By the Numbers:
Why it matters: Refractory mCRC remains one of oncology's toughest challenges, with few effective options after standard therapies fail. Vilamakitug's strong signal in right-sided tumors offers a potential biomarker-driven strategy — a critical step toward more targeted, effective treatment for this patient population.
